(Q33414899)

26 July 2017

title

High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience (English)

1 reference

metastatic renal cell carcinoma

26 July 2017

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Saby George

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Michael Hanzly

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ahmed Aboumohamed

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Terrance Creighton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Lorenzo Digiorgio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ariel Fredrick

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Gaurav Rao

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Diana Mehedint

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Kristopher Attwood

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Eric Kauffman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Deepika Narashima

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Nikhil I Khushalani

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Roberto Pili

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Thomas Schwaab

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

1 May 2014

1 reference

26 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1129-1134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Novel approaches in the therapy of metastatic renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Role of immunotherapy for renal cell cancer in 2011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Guidelines for the safe administration of high-dose interleukin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Immunotherapy and targeted therapy combinations in renal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2014.02.005

10.1016/J.UROLOGY.2014.02.005

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767525%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference